Transcept Pharmaceuticals News

Transcept Pharmaceuticals, Inc. is scheduled to meet with the FDA on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application for IntermezzoA .

Transcept Pharmaceuticals received disappointing news from the FDA regarding the company's New Drug Application for its insomnia treatment.

Main Category: Sleep / Sleep Disorders / Insomnia Also Included In: Regulatory Affairs / Drug Approvals ; Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 30 Oct 2009 - 2:00 PDT Transcept Pharmaceuticals announced that the U.S. Food and Drug Administration issued a Complete Response Letter regarding the New Drug ...

Transcept Pharmaceuticals said Thursday the Food and Drug Administration wants additional safety data on the developing insomnia drug Intermezzo to consider it for regulatory approval.

Transcept Pharmaceuticals announced today that the FDA issued a Complete Response Letter regarding the New Drug Application for IntermezzoA .

Two stocks of note in the past week are Jazz Pharmaceuticals and Transcept Pharmaceuticals .

Transcept Pharmaceuticals, Inc. today announced that it will present at two upcoming healthcare investor conferences.

Transcept Pharmaceuticals, Inc. today announced plans to reduce operating expenses by eliminating certain staff positions following its recently announced License and Collaboration Agreement with Purdue Pharmaceutical Products to commercialize Intermezzo in the United States.

J.C. Penney Co. posted a small loss in the second quarter, just topping Wall Street expectations as the department store chain benefits from inventory controls and other cost-cutting moves.

Just three months ahead of the FDA's action date for Intermezzo, Transcept Pharmaceuticals Inc.

Futures were up sharply pointing to a strong opening of the markets ahead of the release of ISM Manufacturing and Construction Spending economic reports.

Transcept Retains Option to Co-Promote to Psychiatrists Intermezzo under FDA review for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep STAMFORD, Conn.